Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS (Q56608513)
Jump to navigation
Jump to search
article by Jonathan W. Goldman et al published January 2016 in Clinical Lung Cancer
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS |
article by Jonathan W. Goldman et al published January 2016 in Clinical Lung Cancer |
Statements
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS (English)
0 references
January 2016
0 references
17
0 references
1
0 references
80-84
0 references